Terms of the offer
The country’s Federal Medical and Biological Agency (FMBA) has announced that its mRNA-based cancer vaccine , Enteromix, has shown 100% success in preclinical trials. The vaccine not only proved to be safe but also showed powerful tumour-fighting abilities. Scientists in Russia have developed an mRNA-based cancer vaccine, which has reportedly shown 100 per cent efficacy during clinical trials. The vaccine, called Enteromix , now reportedly awaits final approval from the Ministry of Health before being available to the public. Russia has begun trials of a personalized mRNA cancer vaccine that detects tumor-specific mutations, creates a custom vaccine in 7 days, and is offered for free to melanoma patients—blending AI, immunotherapy, and state sponsorship. Russia ’s bold claim of a 100% effective cancer vaccine has sparked global curiosity and caution. Built on personalised mRNA technology, Enteromix could redefine cancer treatment as we know it. But behind the headlines lies a deeper story of small trials, unanswered questions, and expert debate.
